Board of Directors

Randy Benson

Chairman of the Board

Mr. Benson has more than 18 years of experience managing corporate restructurings and turnarounds, most recently as Principal at RC Benson Consulting, Inc. From 2012 to 2016, Mr. Benson was Partner and National Co-leader, Restructuring and Turnaround at KPMG Canada. Prior to that, Mr. Benson held various executive positions in the areas of general management, finance, distribution and logistics. He has also served as Chair of the Ad-Hoc Finance and Investment Committee for the Canadian Stem Cell Foundation.

Maurice Chagnaud


Mr. Chagnaud has more than 25 years of experience in the pharmaceutical sector including senior and leadership roles at Merck KgAa, Merck Generics, Teva, Lupin and Polpharma. Geographically, he has extensive experience working in France, Italy, Germany, Central and Eastern Europe, Russia and the Commonwealth of Independent States, where he managed the commercial activities of generic, OTC and speciality product portfolios.

Frances Cloud


Ms. Cloud has more than 20 years of experience in the pharmaceutical sector, including her time working as an analyst and investment banker for a number of banks, including Nomura International, IMI Securities and Swiss Bank Corporation (now part of UBS). Ms. Cloud established Pharmacloud Research in 2009 to focus on covering the generic medicine industry in Europe, India and the MENA region. Pharmacloud provides specialist advice and consultancy to the pharmaceutical industry and financial investors, including commercial due diligence on off-patent products.

Graeme Duncan


Mr. Duncan has more than 20 years of healthcare and life sciences experience including senior commercial, strategy and general management roles at GlaxoSmithKline, IVAX Pharmaceuticals, and Healthcare at Home. Prior to accepting the interim Chief Executive Officer role at Concordia International Corp., Mr. Duncan previously served as President of Concordia’s International segment since January 2016. Prior to his role as President, he was Managing Director for Concordia’s International segment.

Barry Fishman


Mr. Fishman has approximately 20 years of experience as a business leader, including his recent role as CEO of specialty pharmaceutical company Merus Labs International Inc. (TSX: MSL, NASDAQ: MSLI). In July 2017, European speciality pharmaceutical company Norgine B.V. acquired Merus Labs. His leadership history also includes serving as CEO of Teva Canada for six years, and prior to that, he served as Taro Canada’s CEO. He is also a past Chair of the Canadian Generic Manufacturers Association. Mr. Fishman began his pharmaceutical career at Eli Lilly and spent 17 years at the company in increasingly senior roles. He is currently the CEO of VIVO Cannabis Inc. (TSX-V: VIVO), a licensed producer and distributor of premium pharmaceutical-grade plant-based medicines.

Florian Hager


Mr. Hager is a Principal at GSO Capital Partners based in London, England. He is involved in both debt and equity investments across a wide variety of industries with a specific focus on special situations. Before joining GSO Capital Partners, Mr. Hager worked in Blackstone’s Restructuring & Reorganization Group where he advised debtors and creditors on in-court and out-of-court restructurings. Prior to Blackstone, Mr. Hager worked at Lehman Brothers and Nomura International in London where he was involved in numerous transactions across the industrial and technology sectors including mergers and acquisitions, initial public offerings and leveraged buyouts.

Robert Manzo


Mr. Manzo co-founded Policano and Manzo, LLC, a consulting firm specializing in providing financial services to distressed companies and their lenders. In 2000, Mr. Manzo sold his firm to FTI Consulting, Inc., a global business advisory firm where he held the position of senior managing director through 2005. Since 2006, Mr. Manzo has been a private investor and serves on a number of public and private company boards.